Audit: QRS - Matured Hop Extract for Health & Longevity

Audit conducted on 17/08/2026 02:15 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	85
Failed	0
N/A	8
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Every element traces to the ER: protocol cells to the ER Therapeutic Protocol bullets, time cells to Practical Considerations and Expected Benefits, benefit/risk items to the ER tier headings, all eight monitoring rows and the five qualitative items to the ER Monitoring Protocol & Defining Success table and list.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	Hedges carry over intact: “appears to act on bitter sensors” (ER Conclusion), “neither route shown superior” (ER Beverage route), “the effect appears independent of dose time” (ER Time of day), “no interaction study exists” (ER Prescription drugs, in general).
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	No claim is strengthened or softened. “Chromosomal Damage Signal in Cell Culture” keeps the culture-only qualifier; “Acute Rise in Vagal Tone” keeps “Acute”; the alcohol contraindication stays an avoid, not a caution.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Categories are preserved: benefit-modifying factors (baseline fat, vagal integrity, activity) are not surfaced as cautions, and risk-modifying factors are not surfaced as side effects. Contraindications come only from the ER Populations who should avoid list.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, study citations, author names, NCT identifiers, or brand names appear anywhere in the QRS; the at-a-glance says “the manufacturer” rather than naming Kirin.
1.6	The QRS does not introduce new attributions.	🟢	No new attributions. Where the ER attributes a finding, the QRS either drops the attribution entirely or states the ER’s own hedge; nothing is credited to a source not in the ER.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	The QRS mirrors the ER’s sceptical, evidence-weighted register — small effects, single-sponsor evidence, reassuring safety at the tested dose.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Expert and data-driven (35 mg, 8/12 weeks, numeric marker targets) while remaining readable; the at-a-glance gives the reader what is needed to judge the intervention rather than a verdict.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Presents evidence and measurable targets; no imperative or prescriptive voice anywhere in the sheet.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No advice language. Contraindications are stated as populations and conditions, monitoring as markers and targets, not as instructions to act.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No “recommend”, “advise”, “should”, or “guidance” appears in the document’s own voice.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person address anywhere; no “you” or “your” in any span.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Plain language throughout; necessary specificity (cholecystokinin receptor blockers, Cannabaceae, vagal tone) is carried verbatim from the ER decision-gate bullets and is written out in full rather than as acronyms.
2.8	Information is presented in a concise and very compact manner	🟢	Every item is a single clause; the ER’s multi-sentence bullets are reduced to label-plus-key-fact form throughout the gates, benefits, risks, and monitoring cards.
2.9	It DOES NOT address the reader directly	🟢	Confirmed by full-text scan: the reader is never addressed.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Content is aimed at a proactive optimizer: exact dose, route comparison, decision-relevant funding caveat, and self-trackable markers.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Assumes willingness to run a 12-week trial with baseline and repeat body-composition and attention testing.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Not general-population framing; the monitoring card assumes access to body-composition measurement, liver panels, and hs-CRP.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	Weighting reflects the audience: the at-a-glance leads with the manufacturer-funding limitation and the small size of the effects, which is the decision-relevant signal for this reader.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“anti-aging” does not appear anywhere in the QRS.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	Formal register throughout: “adverse”-grade clinical nouns, “delayed stomach emptying”, “resting heart rate”, “alanine aminotransferase”; no colloquial substitutes.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fixed strings match the template exactly: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”, “Contraindications”, “Key Interactions”, the four tier labels, and “Marker”/”Target”/”Why”.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All template spans present: page_title, header_topic, header_subline_date, header_subline_model, at_a_glance, action_1-3 label/value/sub, time_1-3 label/value/sub, benefits_* (4), stop_items, caution_items, risks_* (4), marker_1-8 name/target/why, monitoring_cadence, qualitative_item_1-5.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	A structural diff against [qrs_template] shows no change outside the variable spans: CSS block, header markup, the website=”evidence_review”/”audit”/”full_review” spans, the cadence paragraph style, and the footer disclaimer are all byte-identical to the template.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section used by the QRS is empty; the ER supplies content for every mapped section. The empty High benefit and High risk tiers are handled under 12.5 / 13.5, not by empty-state phrasing.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	Bold labels are verbatim: “Standard dose”, “Capsule route”, “Duration before judging” from the ER Therapeutic Protocol; all eight interaction labels reproduce the ER bold labels including their parenthetical drug lists.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	No invented labels. Monitoring marker names, benefit and risk headings, and qualitative items reproduce the ER wording; the time-to-effect labels are drawn from the ER Time to effect sentence.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji anywhere in the QRS; the ER’s 🟩/🟥/🟨 tier markers and the “⚠️ Conflicted” flag are not carried over.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Content is condensed rather than extended: every ER bullet is reduced to one clause, no template row or section is duplicated beyond what the ER mandates (8 interactions, 8 markers, 5 qualitative items), and no second-page structure is introduced.

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	The metadata comment at lines 2–14 is the first element after <!doctype html>, ahead of any other comment, head, or body content.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- at line 3 and closing --- at line 13, with the “QRS — Metadata” text before the opening delimiter.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; none of its values are echoed by any rendered element (the visible subline carries only the reformatted date and the model name, which is required by 6.3 / 6.4).
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	All values trimmed and unquoted except duration: "00:03", which contains a colon and therefore requires YAML quoting.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	er_filename: matured_hop_extract_2026-0825-2324_Opus_ER.md (line 4) matches the source ER.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	qrs_prompt_version: 26.7.02 (line 5) matches the version badge of QRS.md.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	qrs_creation_date: 2026-0817-0131 (line 6) is in YYYY-MMDD-HHMM form.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	qrs_creator_ai_nickname: Opus (line 7).
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” is a single word with no version or qualifier.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	qrs_creator_ai_fullname: Opus 5 (line 8).
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” is nickname plus version number with no additional qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	qrs_filename: matured_hop_extract_2026-0825-2324_Opus_QRS.html (line 9) matches the file on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	No leading or trailing whitespace and no unnecessary quoting in any frontmatter value.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., &amp; for &)	🟢	<title>Matured Hop Extract for Health &amp; Longevity - Quick Reference Sheet</title> (line 22) — canonical_topic plus the fixed suffix, with & entity-encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., &amp; for &)	🟢	[header_topic] is “Matured Hop Extract for Health & Longevity” (line 417), the ER canonical_topic entity-encoded.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	[header_subline_date] is 08/17/2026 (line 421), the MM/DD/YYYY form of qrs_creation_date 2026-0817-0131.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	[header_subline_model] is “Opus 5” (line 425), matching qrs_creator_ai_fullname.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	The header carries only the title and the template subline; no badge, version stamp, alternate-names line, source-AI attribution, audit date, or variant marker.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Condenses the ER Conclusion: what the substance is, how it is taken, the gut-sensor route rather than direct tissue action, the small and unreplicated effects, and the reassuring safety at the tested dose.
7.2	[at_a_glance] is no longer than 60 words	🟢	58 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each clause maps to a distinct ER Conclusion passage — the oxidized fraction and dosing form, the gut-wall bitter-sensor route, the small fat and attention changes, the single-sponsor evidence base, and the safety paragraph.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms or specialist classifications; “bitter sensors in the gut wall” replaces bitter taste receptors, “the manufacturer” replaces the named sponsor.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial names, years, sample sizes, or p-values.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No effect sizes, relative risks, confidence intervals, or statistical results; the effects are described only as “small”.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All five items derive from the ER Key Interactions & Contraindications section, specifically its “Populations who should avoid Matured Hop Extract” list.
8.2	[stop_items] represent the Contraindications from the ER	🟢	All five ER avoid-populations are represented, in the same order: hop/Cannabaceae allergy, pregnancy or breastfeeding, under 20, symptomatic gallstone disease, and the beer-plus-alcohol-contraindication case.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Each item is a separate <li> inside the [stop_items] span (lines 567–576).
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Trailing rationale is stripped: “— no reproductive or developmental data exist at any dose”, “the lower age bound of every trial”, and “until the gallbladder question is settled” are all removed.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	The alcohol-contraindication qualifiers are preserved and tightened: “(alcohol use disorder, pancreatitis, advanced liver disease Child-Pugh B or C, pregnancy)” keeps the clinical staging while dropping the “meaning moderate or severe cirrhosis” gloss; “including occupational sensitization” is likewise kept.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in this section.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The section is not empty, and the ER does identify populations that should avoid the intervention, so the emptiness condition correctly does not apply.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not left empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All eight items derive from the bulleted interaction list of the ER Key Interactions & Contraindications section.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	All eight ER interaction bullets are represented in ER order; the beer/alcohol case is not duplicated here because it is already carried as a contraindication.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Each item is a separate <li> inside the [caution_items] span (lines 582–619).
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Reduced to label plus key fact; the ER’s “Severity:”, “Consequence:”, and “Mitigation:” clauses and the mechanistic sentences (e.g. “These block the exact receptor the extract signals through”) are stripped.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Named example drugs are preserved throughout: diazepam, zolpidem, opioids; dexloxiglumide, loxiglumide; semaglutide, liraglutide; diphenhydramine, doxylamine; caffeine, synephrine, capsinoids, green tea catechins; iso-α-acids, rho-iso-α-acids, xanthohumol.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in this section.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The section is not empty, and the ER does identify interactions that change how the intervention is used, so the emptiness condition correctly does not apply.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not left empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three action cells derive from the ER Therapeutic Protocol bullets.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Dose, route, and duration-before-judging are the three decision-critical implementation aspects; lower-value bullets (half-life, split dosing, food, pharmacogenetics, sex, age) are correctly omitted.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER Therapeutic Protocol section contains thirteen distinct actionable bullets, well above three, so no set is unused.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine action spans carry ER-derived content; the subs fold in the ER Beverage route and Time of day bullets rather than repeating the value.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Covers the three time-to-effect aspects named in the ER Practical Considerations “Time to effect” bullet: abdominal fat, attention and vagal measures, and mood and fatigue.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Ordered by benefit magnitude — abdominal visceral fat and attention are both Medium-tier benefits, mood and fatigue is Low-tier and comes last.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER names three distinct time-to-effect aspects, so no set is unused.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine time spans are populated from the ER: 8 weeks for fat separation, a single dosing session for attention and vagal measures, and 6 to 12 weeks for mood and fatigue with the ER’s “about three months” framing.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER does provide time-to-effect information, so the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All items are the ER Expected Benefits sub-section headings.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four tier spans are present and correctly named.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Only the benefit names appear; magnitudes, trial descriptions, participant counts, and mechanistic explanations from the ER are all omitted.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	Parenthetical content is stripped — “Acute Rise in Vagal (Parasympathetic) Tone” becomes “Acute Rise in Vagal Tone”.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	The ER High tier holds no benefit (“No effect reaches this level”), and [benefits_high] is set to style="display: none" with no empty-state text (lines 539–541).

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All items are the ER Potential Risks & Side Effects sub-section headings.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four tier spans are present and correctly named.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Only the risk names appear; the ER’s magnitude paragraphs, relative risks, and concentration thresholds are all omitted.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parenthetical content is carried into any risk item.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	The ER High tier holds no adverse effect, and [risks_high] is set to style="display: none" with no empty-state text (lines 630–632).

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	The table derives from the biomarker table of the ER Monitoring Protocol & Defining Success section.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All eight ER biomarkers are listed in ER order with their functional ranges intact: waist circumference, visceral fat area / body fat percentage, weight and BMI, resting heart rate and HRV, blood pressure, ALT/AST, fasting glucose and HbA1c, and hs-CRP.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	[monitoring_cadence] carries the ER cadence — baseline first, waist and body composition at 4, 8, and 12 weeks, attention task at 6 and 12 weeks, six-monthly thereafter.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	The five items derive from the qualitative-marker list at the end of the ER Monitoring Protocol & Defining Success section.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All five ER qualitative markers are present and complete: sustained attention, late-afternoon mental fatigue, anxiety and mood steadiness, sleep quality, and waistband fit.

Issues 17/08/2026 02:15

Pass rate 100.00%. No issues found.

Issues 17/08/2026 02:04

1. 7.4 — Specialist register in At-A-Glance: “the oxidized bitter fraction of stored hops” (line 434) uses “fraction” in its chemical-separation sense, and “thinly replicated” (line 437) is research jargon; neither is a term a non-specialist would use unprompted or know the exact meaning of.

Fixes 17/08/2026 02:04

1. 7.4 — Plain language in At-A-Glance: Replaced the chemistry- and research-register terms in [at_a_glance] — “oxidized bitter fraction” became “oxidized bitter part”, and “small and thinly replicated” became “small and unconfirmed outside the manufacturer”, wording drawn from the ER Conclusion. The revised text is 58 words, still within the 60-word limit.

Issues 17/08/2026 02:00

1. 9.4 — Mechanistic elaboration in sedatives item: The Key Interactions entry at QRS lines 586–593 ends with “this bitter-acid fraction carries little of the sedative fraction”, a mechanistic elaboration that section 9.4 requires to be stripped; only “additive drowsiness with whole-hop products” is the key fact.
2. 4.5 — Sheet exceeds one-page budget: The Key Interactions gate (eight items, the longest ~230 characters) together with three three-line protocol sub-cells (QRS lines 456–459, 470–474, 484–488) pushes the rendered sheet past the single A4 page the layout budgets for.

Fixes 17/08/2026 02:00

1. 9.4 — Mechanistic elaboration stripped: The sedatives Key Interactions item now ends at “additive drowsiness with whole-hop products”; the trailing clause “this bitter-acid fraction carries little of the sedative fraction” was removed.
2. 4.5 — Protocol sub-cells condensed: Shortened the three protocol sub-cells — dose sub to “Matured hop bitter acids; the only dose ever tested in humans.”, route sub to “Beverage route: 350 mL alcohol-free drink with 35 mg; neither route shown superior.”, and duration sub to “Both trials ran to 12 weeks by design; the effect appears independent of dose time.” — reclaiming rendered lines for the one-page budget.

Issues 17/08/2026 01:54

1. 1.3 — Sedative caution absolutised: The Key Interactions item at line 591 reads “additive drowsiness with whole-hop products, not this bitter-acid fraction”, turning the ER’s hedged “a bitter-acid extract carries little of the sedative fraction” (ER line 254) into a flat denial.
2. 2.15 — Colloquial “maker” for manufacturer: [at_a_glance] at line 437 says “the maker funded nearly every human study”; the ER’s own register is “the manufacturer, Kirin” (ER line 138).

Fixes 17/08/2026 01:54

1. 1.3 — Sedative caution restored: Changed the Key Interactions sedatives item from “additive drowsiness with whole-hop products, not this bitter-acid fraction” to “additive drowsiness with whole-hop products; this bitter-acid fraction carries little of the sedative fraction”, matching the ER’s hedge.
2. 2.15 — Colloquial “maker” replaced: Changed “the maker funded nearly every human study” to “the manufacturer funded nearly every human study” in [at_a_glance].

Issues 17/08/2026 01:47

1. 1.2 / 1.3 — Hedge dropped from mechanism claim: [at_a_glance] at line 435 asserts “It acts on bitter sensors in the gut wall rather than on tissue directly”, while the ER Conclusion it condenses (ER line 418) hedges the same claim as “it appears to trip bitter sensors in the gut wall”.

Fixes 17/08/2026 01:47

1. 1.2 / 1.3 — Hedge restored on mechanism claim: [at_a_glance] changed from “It acts on bitter sensors in the gut wall” to “It appears to act on bitter sensors in the gut wall”, matching the ER Conclusion’s hedged phrasing; the section remains within the 60-word limit at 59 words.

Issues 17/08/2026 01:33

1. 1.3 — Sedative interaction overstated: QRS 585–592 reduces the sedative interaction to a flat “additive drowsiness”, dropping the ER’s own restriction at ER 254 that the caution applies to whole-hop products because “a bitter-acid extract carries little of the sedative fraction”.
2. 4.5 — Sheet overruns one A4 page: At roughly 1.9 A4 pages the sheet is not condensed to the one-page budget; the Key Interactions gate (QRS 584–622) and the Monitoring “Why” column carry near-full ER prose rather than per-section-budgeted text.

Fixes 17/08/2026 01:33

1. 1.3 — Sedative caution restored to ER scope: Changed the sedative interaction consequence from “additive drowsiness” to “additive drowsiness with whole-hop products, not this bitter-acid fraction”, restoring the severity restriction stated at ER 254.
2. 4.5 — Key Interactions gate condensed: Trimmed three interaction items — the over-the-counter parenthetical from “sedating antihistamines such as diphenhydramine and doxylamine, hop-containing sleep aids” to the bare drug list, “unintended stacking with no combined safety data” to “unintended stacking, no combined safety data”, and “overlapping rather than additive effects” to “overlapping, not additive, effects” — with every named example drug preserved.
3. 4.5 — Monitoring “Why” column shortened: Condensed all eight rationale cells (e.g. “Liver enzymes, released when liver cells are stressed; safety marker for a novel botanical” to “Liver enzymes; safety marker for a novel botanical”), and the hs-CRP cell now carries the ER’s caveat “no human anti-inflammatory effect shown” in place of the mechanistic restatement.
4. 4.5 — Cadence and protocol subs tightened: Reduced the cadence line to “Baseline first; waist and body composition at 4, 8, and 12 weeks, attention task at 6 and 12 weeks; six-monthly thereafter.” and shortened all three protocol sub-lines plus the abdominal-fat time-to-effect sub-line.
5. 4.5 — Contraindication item shortened: Reworded the beer item to “Beer as the source with any alcohol contraindication (…, advanced liver disease Child-Pugh B or C, pregnancy)”, keeping the Child-Pugh staging intact.